# Pinwheel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pinwheel-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Total disclosed funding: $20M
- Latest round: Series A (Feb 4, 2026)
- Investors on record: 2

## About

Based in the US, Pinwheel Therapeutics is a clinical stage biopharmaceutical company focused on the development of therapeutic assets for emergency anticoagulation management. In February 2026, Pinwheel Therapeutics raised USD 20 million in venture funding from investor 108 BioCapital and Claypond Capital. 

Pinwheel’s lead asset, Ciraparantag, is a small molecule therapy manufactured using peptide chemistry. It is designed to reverse multiple classes of anticoagulants, including direct oral Factor Xa inhibitors, direct thrombin inhibitors, and both low molecular weight and unfractionated heparins. The therapy is being developed as a universal reversal option delivered via a ready to use intravenous injection for emergency settings such as trauma, intracranial hemorrhage, and urgent surgery.

## Funding rounds

- Series A, Feb 4, 2026, $20M — Claypond Capital, 108 Biocapital

## Investors

- Claypond Capital — Series A
- 108 Biocapital (https://capitalatlas.ai/funds/108-biocapital) — Series A